Iodomethane

Iodomethane

SCHEMBL4047719

CI.Cc1nc2ccccc2s1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.50
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
TDP1 Q9NUW8 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HSD17B10 Q99714 3/20 0.50
MAPT P10636 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
HPGD P15428 2/20 0.50
ADRA2A P08913 1/20 0.50
FBP1 P09467 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
DRD2 P14416 1/20 0.50
ALOX15 P16050 1/20 0.50
ADRA2B P18089 1/20 0.50
ADRA2C P18825 1/20 0.50
DRD1 P21728 1/20 0.50
MC5R P33032 1/20 0.50
OPRM1 P35372 1/20 0.50
DRD3 P35462 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55837 0.96 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
SCHEMBL30074811 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
Ammonia Solution, Strong SCHEMBL4408280 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
SCHEMBL10665140 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
Hydrochloric Acid SCHEMBL7776250 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
Iodide SCHEMBL4618865 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
SCHEMBL2148044 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
Bromide SCHEMBL887893 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
Water SCHEMBL28902586 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1
SCHEMBL10669342 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ATDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105885466-A Synthesis method of monomethine cyanine dye 付义乐 2016-08-24 CN disclosed
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED 2009-10-01 US disclosed
EP-2029584-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE Cancer Research Technology Limited (GB) 2009-03-04 EP disclosed
WO-2007096618-A2 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247579-A1 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE RB1, RBBP5, RRM2B SMN1; SMN2 2177/4885NPC1 3790/4885RAB9A 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.